Gastric Cancer
Conditions
Brief summary
Sintilimab in Combination With Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant Therapy in patients With Resectable Locally Advanced Gastric Cancer
Detailed description
This prospective, multicenter, single-armed, phase II study will evaluate efficacy and safety of Sintilimab in combination with Xelox (Oxaliplatin 130mg/m2 iv d1 Q3w and Capecitabine 1000mg/m2 po Bid d1-14 Q3W) as neoadjuvant therapy in patients with resectable locally advanced gastric or gastroesophageal adenocarcinoma(G/GEJ AC). Newly diagnosed, treatment naïve patients with resectable locally advanced gastric or G/GEJ AC will be eligible to receive up to 3 cycles of sintilimab plus Xelox regimen as neoadjuvant therapy. Following radical gastrectomy will be performed within one to four weeks since last dosing for patients with resectable cancer after radiological evaluation.
Interventions
DRUGSintilimab
3 cycles before radical surgery
DRUGOxaliplatin
85mg/m2 Q3W, 3 cycles perioperation
DRUGCapecitabine
1000mg/m2 bid po D1\ 14 Q3W, 3 cycles perioperation
Sponsors
First Affiliated Hospital of Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
neoadjuvant chemotherapy sintilimab plus XELOX
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically proven adenocarcinoma of the stomach. 2. The primary tumor locates at stomach or esophagogastroesophageal ic junction. 3. Clinical T3-4NxM0 disease, confirmed by enhanced contrast abdominal computed tomography (CT) or magnetic resonance imaging (MRI). 4. At least one measurable lesion. 5. Resectable gastric or gastroesophageal cancer, judged by surgeons in this studyEligible and reasonably suitable for potentially curative resection 6. ECOG performance status 0-1. 7. Adequate organ function for chemotherapy and surgical treatment, as evaluated by laboratory tests. 8. Written (signed) informed consent. 9. Good compliance with the study procedures, including lab and auxiliary examination and treatment. 10. Agree to use an approved contraceptive method during the treatment period, until 120 days after last dose of Sintilimab or 180 days after last dose of chemotherapy.
Exclusion criteria
1. Unsectable primary tumor or any distant metastatic disease. 2. Received any anti-cancer therapy for this disease, including radiation therapies, chemotherapies, immunotherapies, and Chinese traditional herb therapies. 3. Clinical T1-2N0M0 disease, confirmed by CT/MRI or endoscopic ultrasonography. 4. Active autoimmune disease or history of refractory autoimmune disease. 5. History of any other malignant tumor within 2 years, excluding cured local tumor, such as resected skin basal cell or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or ductal carcinoma in situ (DCIS). 6. History of gastrointestinal hemorrhage within 2 weeks before enrollment or patients with a high risk of hemorrhage. 7. History of gastrointestinal perforation within 6 months before enrollment. 8. Gastrointestinal obstruction, gastrointestinal dysfunction, or malabsorption syndrome that may affect the absorption of Capecitabine. 9. Weight loss is greater than 20% within 2 months before enrollment. 10. History of severe pulmonary disease, including but not limited to interstitial pulmonary disease, noninfectious pneumonitis, pulmonary fibrosis, acute pulmonary disease 11. Uncontrolled systematic disease, including diabetes mellitus, hypertension, etc. 12. Severe chronic or active infectious disease that needs systematic antibiotics, antifungal, or antiviral therapies. 13. Untreated chronic hepatitis B, serum HBV DNA load higher than the lower threshold of the test, or HCV RNA positive. 14. With any cardiovascular risk factors as follow: 1. History of angina within 28 days before enrollment, defined as moderate pain affecting daily activities; 2. History of symptomatic pulmonary embolism within 28 days before enrollment; 3. History of acute myocardial infarction within 6 months before enrollment; 4. History of NYHA class III/IV heart failure within 6 months before enrollment; 5. History of grade 2 (Lown grading system) or menopause ventricular arrhythmias or history of supraventricular arrhythmias that needs treatment within 6 months before enrollment; 6. History of cerebrovascular accident within 6 months before enrollment; 15. grade 1 Peripheral neuropathy , excluding patients with only deep tendon reflex absence.\] 16. Known Dihydropyrimidine dehydrogenase (DPD) deficiency. 17. Known allergic to any drug used in this study. 18. History of allogeneic hematopoietic stem cell transplantation or organ transplantation. 19. Receiving corticosteroid (\> 10mg/d prednisone or equivalent dose of steroids) or other systematic immunosuppression therapies within 14 days before enrollment, excluding following therapies: 1. steroid hormone replacement therapy (≤10mg/d); 2. local steroid therapy; 3. short-term, prophylactic steroid therapy for preventing allergies or nausea and vomiting 20. Receiving attenuated vaccine within 4 weeks before enrollment. 21. Receiving immunotherapy or other study drugs within 28 days before enrollment, 22. History of receiving anti-PD-1, anti-PD-L1, anti-PD-L2, or any other T cell co-simulation or checkpoint inhibitor therapy. 23. Receiving major surgery within 28 days before enrollment. 24. For patients with uncontrolled epilepsy, central nervous system disease, or mental disorder, researchers should evaluate if the inform consent and/or the compliance would be affected by their disease. 25. Any drug or alcohol abuse that would affect drug management or toxicity analysis. 26. Pregnant or nursing female.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological complete response rate (pCR) | after surgical resection (up to 12 weeks after first dosing) | evaluate pathological complete response rate of primary tumor and locally metastatic lymph nodes after 3 cycles of neoadjuvant therapy. |
Secondary
| Measure | Time frame |
|---|---|
| Tumor regression grade (TRG) | after surgical resection (up to 12 weeks after first dosing) |
| Objective response rate (ORR) | 9 to 12 weeks |
| Disease free survival (DFS) | every 90 days after resection, up to 2 years |
| 1-year overall survival rate | 1 years |
| 2-year overall survival rate | 2 years |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cytokine (IL-6) | up to 12 weeks after first dosing | The relation between treatment efficacy and biomarker in peripheral blood |
| immune cell subpopulation (CD3, CD4, CD8 lymphocytes ) | up to 12 weeks after first dosing | The relation between treatment efficacy and biomarker in peripheral blood |
| PD-L1 expression, tumor infiltrating lymphocytes (TIL), etc. | after surgical resection (up to 12 weeks after first dosing) | The relation between treatment efficacy and biomarker in tumor tissue |
| Overall survival (OS) | up to 5 years | The relation between overall survival and pathological response after neoadjuvant therapy of Sintilimab plus Xelox for gastric cancer |
Countries
China
Contacts
Primary ContactHaiping Jiang, PhD
Outcome results
None listed